William M. Moore - 13 Jun 2025 Form 4 Insider Report for IRIDEX CORP (IRIX)

Reporting relationship: Director
Issuer ticker: IRIX
Reported as of: 13 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jun 2025, 20:17:04 UTC
Prior SEC filing: 13 Jun 2025
Next SEC filing: 19 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Nilo De Castro, Attorney-in-fact for William Moore

Key filing fact

William M. Moore filed Form 4 for IRIDEX CORP (IRIX) on 24 Jun 2025.

Key facts

This page summarizes William M. Moore's Form 4 filing for IRIDEX CORP (IRIX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 24 Jun 2025, 20:17.

Change

Previous filing in this sequence was filed on 13 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001217126 Primary reporting owner

MOORE WILLIAM M

Relationship: Director
Address: 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW
Signature: /s/ Nilo De Castro, Attorney-in-fact for William Moore
Signature date: 24 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IRIX transaction Derivative

Common Stock (right to buy)

Award

Transaction value: $0
Shares: +53,000
Change %
Price: $0.000000
Shares after: 53,000
Date: 13 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 53,000
Exercise price: $0.9400
Footnotes: F1, F2

IRIX transaction Derivative

Common Stock (right to buy)

Award

Transaction value: $0
Shares: +15,000
Change %
Price: $0.000000
Shares after: 15,000
Date: 13 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $0.9400
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This option was granted pursuant to the Company's 2008 Equity Incentive Plan, as amended, and is exempt pursuant to Rule16b-3.

Footnote F2

All shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the Company's 2026 annual meeting of stockholders.

Footnote F3

The shares are subject to vesting according to the following schedule: 1/48 of the total number of shares subject to the option shall vest on July 13, 2025, and each month thereafter, such that the option shall be fully vested on the earlier of (i) the four-year anniversary of the grant date or (ii) the Company's 2029 annual meeting of stockholders.